



CONTACT:

Heidi Sanborn, Executive Director

(916) 402-3911 or heidi@calpsc.org

Robert Kloppenburg, Vice President, North America Communications

(908) 275-6388 or robert.kloppenbourg@ipsen.com

Sara Campbell, Centron Public Relations

(646) 722 8812 or scampbell@centronpr.com

**IPSEN BIOPHARMACEUTICALS, INC. RECEIVES STATEWIDE AWARD FOR
ACHIEVEMENTS IN PRODUCT STEWARDSHIP**

FOR IMMEDIATE RELEASE

Sacramento, CA – August 4, 2015. Ipsen Biopharmaceuticals, Inc. is one of four companies operating in California who will be honored by the **California Product Stewardship Council** (CPSC) during the organization's 6th Annual Arrow Awards ceremony held at the Millennium Biltmore Hotel in Los Angeles on August 6, 2015 at the **California Resource Recovery Association's** 39th annual conference and tradeshow.

Ipsen Biopharmaceuticals is the winner of the Green Arrow Award for System & Design Innovations. This award is given to a company that demonstrates an innovative product, package or system-approach that removes or reduces toxic or other problematic attributes present in other similar products.

Ipsen Biopharmaceuticals is a pharmaceutical company with 18 full time employees in California. Based on its product stewardship strategy, Ipsen launched its innovative medication delivery system of Somatuline® Depot (lanreotide) Injection in the US market in 2014.

“We are dedicated to developing and delivering innovative solutions to help improve the lives of patients as well as reduce medical waste and packaging and are honored to receive this award from the California Product Stewardship Council,” said Cynthia Schwalm, Chief Executive Officer, Ipsen Biopharmaceuticals, Inc. “Safe’n’Sound® technology, which is incorporated into the delivery system for our product Somatuline® Depot, reduces waste as well as helps prevent needle stick injuries.”

Ipsen's new delivery system has a needle that automatically retracts after the medication has been administered, eliminating the presence of free needles and resulting in a reduction of 50 percent of used needle waste. Supplied as a prefilled syringe, the product requires no reconstitution eliminating the need for vials. A plunger protector is included that helps guard against loss of medication. These features, coupled with a low volume formulation, have resulted in an estimated reduction in mass of medical waste generated of 40 percent per dose versus prior formulations of the product. The syringes and needle cap are manufactured without latex or natural dry rubber. Furthermore, the product is manufactured without solvents, resulting in a toxics reduction of 53 tons of solvents. It is estimated that 67 tons of carbon dioxide are avoided per year from this new delivery system, as well as a reduction of 6,083 pounds of packaging.

“We are pleased to select Ipsen for the Green Arrow Award for System & Design Innovations as Ipsen has not only taken the initiative to reduce the waste, toxic substances, and GHG emissions typically associated with this therapy, their innovative new delivery system also helps protect medical professionals and sanitation workers from needle stick injuries,” said Heidi Sanborn, Executive Director, CPSC.



Photo Courtesy of Ipsen Biopharmaceuticals, Inc.

-XXXXX-

California Product Stewardship Council (CPSC) educates both the public and private sectors about Product Stewardship and closely partners with business, jurisdictions, waste and recycling companies, manufacturers and others to promote and encourage sustainable practices and to recognize those companies who are taking a leadership role in participating in waste reduction and recycling. For more information, please go to: www.CalPSC.org.

Ipsen Biopharmaceuticals, Inc. is a global specialty-driven pharmaceutical company with total sales exceeding EUR1.2 billion in 2014. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to EUR260 million, representing more than 21 percent of Group sales. Moreover, Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information, visit www.ipсен.com.